Regen BioPharma

RGBP

Biotechnology · Healthcare

Price

$0.00

+0.00 (-37.50%)

Market Cap

$3,155

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+1071.4% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.0M (2021) → 23.5M (2025)

Regen BioPharma is a small biotechnology company focused on developing new drugs using the body's immune system. It researches treatments for cancer and other serious diseases, with a particular focus on a technology called RNA interference, which can "switch off" certain genes that help diseases grow. The company is in the early stages of drug development and does not yet sell any approved products to patients or hospitals.

Regen BioPharma earns almost no revenue today and funds its research primarily through stock offerings and financing arrangements. It operates mainly in the United States and is a micro-cap company with a market value well under $100 million. Because it has no approved drugs and no steady revenue stream, the company faces significant financial risk — it must continue raising outside capital to survive, and there is no guarantee its experimental treatments will ever reach the market or receive regulatory approval.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-46.4% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+100.0% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$11,725/ year

↓ Declining (-92% vs prior year)

5.0% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

3.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~0 months

$271 cash & investments

Quarterly Free Cash Flow

Short runway — potential dilution ahead through share issuance

Cash watch

Regen BioPharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

0.0%

Thin — 0.0% gross margin

Operating Margin

-485.8%

Losing money on operations — -485.8%

ROCE

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-11.6%

Shrinking sales (-11.6% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

-163%

Weak — only -163% of profit becomes cash

FCF Margin

-181.9%

Burning cash (-181.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial